46 results about "Toxic dose" patented technology

The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells by providing HAART simultaneously. Compositions of the invention comprise an activator of latent HIV expression, such as prostratin, and an inhibitor of histone deacetylase, such as TSA. A surprising finding of this invention is that the inhibitor of the histone deacetylase synergizes the effect of prostratin thus, allowing administering to a patient a lower, non-toxic dose of prostratin.

The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size. In contrast to classic Sags, the egc superantigens induced minimal toxicity, are rarely associated with the presence of preformed antibodies and are used as a plurality with a broad T cell Vβ profile. Useful egc superantigen compositions for parenteral administration native egc enterotoxins, homologues, fragments and fusion proteins of native egc enterotoxins capable of activating a broad spectrum of T cells expressing T cell receptor/α motifs. T cell survival-enhancing cytokines IL-7, Il-15, Il-23 are used. together with parenteral egc SE therapy. Also disclosed is combined therapy that includes parenteral, intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs or (iii) radiation therapy or (iv) anti-angiogenic and tyrosine kinase inhibitors.

An intravascular stent especially suited for implanting in curved arterial portions. The stent retains longitudinal flexibility after expansion. The stent is formed of intertwined meander patterns forming triangular cells. The triangular cells are adapted to provide radial support, and also to provide longitudinal flexibility after expansion. The triangular cells provide increased coverage of a vessel wall. The stent can have different portions adapted to optimize radial support or to optimize longitudinal flexibility. Loops in the stent are disposed and adapted to cooperate so that after expansion of said stent within a curved lumen, the stent is curved and cells on the outside of the curve open in length, but narrow in width whereas cells on the inside of the curve shorten in length but thicken in width to maintain a density of stent element area which much more constant than otherwise between the inside and the outside of the curve. As a result, when the stent is coated with a medicine the more constant density of stent elements results in an even dose being applied to the inside wall of the lumen, avoiding the possibility that a toxic dose be supplied at one area while a less than effective dose is applied to another area.

The present invention relates to the effect of naturally occurring compounds on tumor development. As an example of proof, we used low; non-toxic doses of three compound e.g. Calcium D-glucarate, a naturally occurring Ca⁺⁺ salt of D-glucaric acid; Nicotinamide (NA), a naturally occurring vitamin and butyric acid (BA), a naturally occurring saturated short chain fatty acid. 7,12 dimethylbenzanthracene (DMBA), which is a very potent skin carcinogen and is an environmental pollutant, was used for skin tumor development. Experiment was performed upto 30 weeks. All the above-mentioned compounds were used either alone or concomitantly any two or all the three. In the positive control group 100% tumorigenesis was attained in 28 weeks, use of single compound led to the inhibition of DMBA induced tumorigenesis between 33 to 47%, use of two compounds resulted in the 73 to 80% reduction in tumorigenesis but the concomitant use of three compounds resulted into 100% inhibition of tumor development at the end of 30 weeks. This led us to conclude that the concomitant use of Cag, NA and BA in combination of two is useful for preventing skin tumor develoment for a sort or long period of time. But the concomitant use of all the three compounds, as described, exhibited the perfect synergistic effect in preventing the tumor development completely. This strategy should be equally effective in the management of benign and possibly malignant tumor in any organ caused by any mean.

A series of compounds of general structure I and metal salts thereof. These compounds are useful in the treatment of diabetes mellitus and associated conditions when administered in an effective non-toxic dose in the form of a pharmaceutically acceptable composition resulting in cell regeneration.wherein for example,R=H, R1=H, R2=Me, R3=Meand R4=

The present invention provides a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity. This composition has a high gene transfection efficiency at non-toxic doses and is designed to transfect human bronchial premalignant lesions and early endo-bronchial malignancies. Also provided is a method of method of treating a cancerous or pre-cancerous condition of the respiratory tract in an individual in need of such treatment, comprising the step of administering to said individual a pharmacologically effective dose of a pharmaceutical composition, comprising: (a) cationic lipids, wherein said lipids are a liposomal mixture of a diacyl-ethyl-phosphocholine and 1,2-diacyl-sn-glycero-3-phosphoethanolamine; and (b) a plasmid cDNA sequence encoding a protein having tumor suppressor or pro-apoptotic activity.

The invention discloses a method for controlling the quality of yanaconitine which is toxic ingredient in Yunnan Hongyao capsule, and pertains to the technical field of drugs. The method comprises: controlling the toxicity of the crude drug prepared kusnezoff monkshood root, controlling the content of the yanaconitine in the capsule, controlling the toxicity of the crude drug prepared kusnezoff monkshood root by animal safety test, and detecting the content of the toxic ingredient yanaconitine by high performance liquid chromatography. The toxic dose of the crude drug prepared kusnezoff monkshood root is not more than 2g/kg, the content of the yanaconitine per capsule is not more than 0.01mg, a chromatographic column is U-bondapaKCN with the volume of 7.8 multiplied by 300mm; a mobile phase is methanol-water-ammonia water (35:65:0.5); the column temperature is 30 DEG C; the detection wavelength is 260nm; the flow rate is 2mL/min; and the theoretic number of column plates is not less than 4100. The method has the advantages of comprehensive monitoring means, simple and graspable operations, and high detection accuracy and precision; the method enhances the controllability of the toxic ingredient of the Yunnan Hongyao capsule, and better ensures the processing qualification of the crude drug prepared kusnezoff monkshood root and the drug safety.

An intravascular stent especially suited for implanting in curved arterial portions. The stent retains longitudinal flexibility after expansion. The stent is formed of intertwined meander patterns forming triangular cells. The triangular cells are adapted to provide radial support, and also to provide longitudinal flexibility after expansion. The triangular cells provide increased coverage of a vessel wall. The stent can have different portions adapted to optimize radial support or to optimize longitudinal flexibility. Loops in the stent are disposed and adapted to cooperate so that after expansion of said stent within a curved lumen, the stent is curved and cells on the outside of the curve open in length, but narrow in width whereas cells on the inside of the curve shorten in length but thicken in width to maintain a density of stent element area which much more constant than otherwise between the inside and the outside of the curve. As a result, when the stent is coated with a medicine the more constant density of stent elements results in an even dose being applied to the inside wall of the lumen, avoiding the possibility that a toxic dose be supplied at one area while a less than effective dose is applied to another area.

The present invention relates to methods for decreasing cellular DNA repair in a target patient; decreasing cellular NAD⁺ biosynthesis in a target patient; increasing efficiency of radiation therapy in a target patient; modulating nicotinamide phosphoribosyl transferase activity in a patient; or sensitizing a patient to a DNA damaging therapy. The invention relates to methods for treating a patient who received a toxic dose of an nicotinamide phosphoribosyl transferase inhibitor. The invention also relates to pharmaceutical compositions comprising a physiologically acceptable carrier; an effective amount of a NMPRT inhibitor; and nicotinic acid. The invention also relates to methods for treating a patient diagnosed with or suspected to have a cancer deficient in nicotinic acid pathway.

The invention relates to the field of clinical overcoming of drug resistance of tumors and combined medication, in particular to EGFR-TKIs which can overcome the drug resistance of non-small cell lungcancer by lowering cholesterol. Statins can enhance the antitumor efficacy of EGFR-TKIs. The invention discloses the fact that MbetaCD is used for removing cholesterol from human non-small cell lungcancer cell lines PC-9/GR and H1975 to enhance the efficacy of gefitinib in resisting the non-small cell lung cancer, enhance the inhibition to signal pathways and enhance the affinity of EGFR and EGFR-TKIs. The statins can synergize with EGFR-TKIs in resisting tumors, inhibit the signal pathways and enhance the affinity of EGFR-TKIs and EGFR without toxic doses, and at the same time, the synergistic anti-tumor efficacy of combined use of the statins and EGFR-TKIs is verified on PC-9 and H1975 nude-mouse transplanted tumor models.

Disclosed are compositions and methods of treatment with uridine-based and phosphoadenosine-based cofactors for the prevention and treatment of toxicity associated with compounds such as acetaminophen, which undergo Phase II glucuronidation and sulfonation in the liver. Uridine diphosphoglucose, phosphoadenosine-phosphosulfate, and their derivatives can be administered exogenously either to prevent their depletion in the liver during treatment with acetaminophen, or to replace depleted substrates of UDPGA-transferase or PAPS-transferase in order to treat an individual after a toxic dose of acetaminophen has been ingested.

A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of Mycobacterium indicus pranii with Cyclophosphamide. This disclosure generally relates to the field of cancer biology. More specifically, this disclosure relates to the immunotherapeutic treatment of myeloma and thymoma, using a combination of heat killed Mycobacterium indicus pranii and the widely administered chemotherapeutic drug, Cyclophosphamide. Mycobacterium indicus pranii has already shown its efficacy as an immunomodulator and has been safely administered to humans. The most common method of cancer management is the application of chemotherapeutic drugs which results in side-effects. At lower non-toxic doses Cyclophosphamide is not effective. The present disclosure discloses a method of improving efficacy of non-toxic doses of Cyclophosphamide by administrating it together with Mycobacterium indicus pranii. This disclosure is relevant for the treatment of other lymphomas as well.

The invention relates to an animal feed, and provides a processing method of rapeseed meal, the method comprises the following steps: detoxificating and decolouring of the rapeseed meal, mixing sodium dithionite, rapeseed meal with water and heating. The invention overcomes the defects of incomplete detoxification, large restriction of geography, influenced nutrition value of rapeseed meal, high cost or difficult popularization of equipments in the present detoxification reaction of rapeseed meal, and when the rapeseed meal content in feed exceeds 2-5%, the feed turns black and is unbeneficial to the sale and usage, so that the invention provides the rapeseed meal and its processing method, and the animal feed containing the rapeseed meal. The processing method of the rapeseed meal realizes a continuous processing of detoxificating and decolouring of the rapeseed meal at same time, and has the advantages of low cost for decolouring, good detoxificating efficiency with residual toxic dose less than 0.2 mg/kg, high safety performance and simple technology, the rapeseed meal and its processing method are suitable for industrial application, and the adding proportion of the processed rapeseed meal can reach 5-15%.

The invention discloses an application of Danjie emodin in preparation of a medicine for preventing and treating African swine fever virus. The Danjie emodin disclosed by the invention has a remarkable effect of resisting the African swine fever virus. The maximum non-toxic dose of the Danjie emodin is 40 mu M, and the Danjie emodin can effectively inhibit infection and proliferation of the African swine fever viruses, can be used as the medicine for preventing and treating African swine fever, and has a very good application prospect in the aspect of preventing and treating the African swine fever.